Recombinant human α‐interferon in patients with chronic non‐A, non‐B hepatitis: A multicenter randomized controlled trial from France
Recombinant human α‐interferon in patients with chronic non‐A, non‐B hepatitis: A multicenter randomized controlled trial from France
复制标题
重组人α-干扰素治疗慢性非甲非乙型肝炎：来自法国的一项多中心随机对照试验
DOI：
10.1002/hep.1840130302
复制
发表时间：
1991
期刊：
影响因子：
13.5
通讯作者：
J. Benhamou
中科院分区：
文献类型：
--
作者：
P. Marcellin;N. Boyer;E. Giostra;C. Degott;A. Couroucé;F. Degos;Henri Coppere;P. Calès;P. Couzigou;J. Benhamou
我们进行了一项多中心随机对照试验，比较了两种剂量的重组人α -干扰素对60例慢性非甲、非乙型肝炎患者的疗效。30例患者的感染源似乎是输血，16例患者的感染源是静脉药物滥用，14例患者的感染源不明。患者被随机分配到不治疗组或1或3mu的α -干扰素治疗组，每周给予3次，持续24周。45例（75%）患者丙型肝炎病毒抗体阳性。
We have conducted a multicenter randomized controlled trial comparing two doses of recombinant human α‐interferon for efficacy in 60 patients with chronic non‐A, non‐B hepatitis. The source of infection appeared to be transfusion in 30 patients, intravenous drug abuse in 16 patients and was unknown in 14 patients. Patients were randomly assigned to no treatment or to treatment with either 1 or 3 MU of α‐interferon given three times a week for 24 wk. Forty‐five patients (75%) were positive for antibody to hepatitis C virus.